Navigation Links
Cell Therapeutics Second Quarter Net Loss Decreases 54%; Pixantrone NDA Submitted to the FDA for Approval
Date:8/5/2009

2008 2009 2008 ---- ---- ---- ---- Revenues: Product sales $- $2,870 $- $6,244 License and contract revenue 20 20 40 40 --- --- --- --- Total revenues 20 2,890 40 6,284 --- ----- --- ----- Operating expenses, net: Cost of product sold - 767 - 1,657 Research and development 7,320 15,857 15,276 31,712 Selling, general and administrative 10,580 11,518 19,330 22,728 Amortization of purchased intangibles - 537 - 934 Restructuring charges 3,820 - 3,944 - Gain on sale of investment in joint venture - - (10,244) - --- --- ------- --- Total operating expenses, net 21,720 28,679 28,306 57,031 ------ ------ ------ ------ Loss from operations (21,700) (25,789) (28,266) (50,747) Other income (expense): Investment and other income, net 37 93 71 353 Interest expense (1,583) (2,395) (3,200) (4,380) Amortization of debt discount and issuance costs (497) (30,202) (5,348) (41,146) Foreign exchange gain (loss) 54 76 95 (2,161) Make-whole interest expense - (25,596) (6,345) (33,377) Gain on derivative
'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. DJO Incorporateds Pending Merger With ReAble Therapeutics Clears U.S. Antitrust Review
3. PeriCor Therapeutics Announces Closing of Licensing Agreement for Acadesine with Schering-Plough Corporation
4. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
5. Amsterdam Molecular Therapeutics to Release H1 2007 Results on August 29, 2007
6. Nektar Therapeutics Appoints Tim Harkness as Chief Financial Officer
7. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
8. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
9. Amsterdam Molecular Therapeutics Reports Half Year Results 2007
10. Nektar Therapeutics Appoints Lutz Lingnau as New Board Member
11. Anesiva Grants Specific-Use License of Its Needle-Free Drug Delivery Technology to Particle Therapeutics for Diabetes Drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2015)... 30, 2015 Oxford Finance LLC ("Oxford"), a ... sciences and healthcare services companies, today announced the closing ... with Celula, Inc., a diagnostic testing company focused on ... patient care and improved outcomes.  Proceeds of the loan ... the commercialization of its products in the U.S. and ...
(Date:4/30/2015)... April 30, 2015  Asterias Biotherapeutics, Inc. (NYSE MKT: ... of regenerative medicine, today announced that it will release ... 7, 2015 after the close of the U.S. financial ... webcast on Thursday, May 7, 2015 at 4:30 p.m. ... and recent corporate developments. For both "listen-only" ...
(Date:4/30/2015)... SureClinical, a leader in cloud-based health ... joined SureClinical’s executive team as Chief Financial Officer. ... executive with over 25 years in leadership roles ranging ... Ms. Morris joins SureClinical from Marrone Bio Innovations (MBI), ... of MBI from its founding in 2006 until 2011, ...
(Date:4/29/2015)... (TSX-V: BRM) ("Biorem" or "the Company") today announced its results for the ... year-end financial statements and MD&A have been filed on SEDAR ( www.sedar.com ... 2014 , 2013 Revenue 3,968 , 5,121 ... , 1,703 , 2,231 , 5,866 Operating  ... , 4,562 Ebitda* 92 , 418 , ...
Breaking Biology Technology:Oxford Finance Provides $10 Million Debt Financing to Celula 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 2Asterias Biotherapeutics to Report First Quarter Results on May 7, 2015 3Julie I. Morris Joins SureClinical as Chief Financial Officer 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 2Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 3Biorem Reports Results for Fourth Quarter 2014 and Year Ended December 31, 2014 4
... EXTON, Pa., Feb. 28, 2012 ViroPharma Incorporated (Nasdaq: ... fourth quarter and year ended December 31, 2011. ... in annual net product sales, including $251 million in net ... in net sales of Vancocin® (Vancomycin Hydrochloride Capsules, USP); ...
... NOVATO, Calif., Feb. 28, 2012 Ultragenyx Pharmaceutical ... for rare and ultra-rare genetic disorders, today announced ... has granted orphan drug designation for UX003 for ... an extremely rare autosomal recessive lysosomal storage disorder ...
... Verenium Corporation (Nasdaq: VRNM ), a leading ... high-performance enzymes, today announced that it will release ... 5, 2012 at 8:00 a.m. ET. In conjunction with the ... webcast on Monday, March 5 at 8:30 a.m. ET. ...
Cached Biology Technology:ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 2ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 3ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 4ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 5ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 6ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 7ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 8ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 9ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 10ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 11ViroPharma Incorporated Reports Fourth Quarter and Full Year 2011 Financial Results 12Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 2Ultragenyx Granted Orphan Drug Designation for UX003 for the Treatment of Mucopolysaccharidosis Type 7 (MPS 7) 3Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 2Verenium Corporation to Announce Fourth Quarter and Year-End 2011 Financial Results 3
(Date:3/30/2015)... , Mar. 26, 2015 Research and Markets ... of the "Global Gesture Recognition Market in Automotive ... The analysts forecast the Global Gesture Recognition market in ... over the period 2013-2018. Gesture recognition is ... to different gestures of an individual. Gesture recognition technology ...
(Date:3/24/2015)... DUBLIN , Mar. 24, 2015 Research and Markets ... "Face and Voice Biometrics - Global Strategic Business Report" report ... for Face and Voice Biometrics in US$ Thousands by the following ... analytics for the US, Canada , ... , Middle East & ...
(Date:3/23/2015)... -- SoundView Technology Group issues a new research update following ... smart wallet. SoundView was one of the selected user groups to ... Wocket in multiple scenarios and outlets. Soundview ... making both debit and credit card payments.  ... company meets their plans in 2015, it would push our ...
Breaking Biology News(10 mins):Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 2Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 3Technology Research Note Update from SoundView; Real-World Usage and Feedback of Wocket Smart Wallet at CVS, Whole Foods and other Retailers 4
... of Appeals has overturned an August 2010 ban on federal ... broader exploration of how stem cells function and how they ... incurable diseases. The ruling has been welcomed by the ... and by the nation,s top researchers in the field, including ...
... 27, 2011 According to the Centers for Disease Control ... more likely to die from diabetes than someone living in ... parts of the United States. Now, a group of seven ... change those health disparities and improve health through the creation ...
... A gene therapy approach using a protein called ... of age-related macular degeneration (AMD), according to a new ... of Medicine. Led by senior author Rajendra Kumar-Singh, PhD, ... delivered by a gene therapy approach significantly reduced the ...
Cached Biology News:US Appeals Court opens federal funding for stem cell research 2Network created to address obesity, chronic health issues in Appalachian region 2Network created to address obesity, chronic health issues in Appalachian region 3Gene therapy shows promise against age-related macular degeneration 2
6X DNA Gel Loading Buffer is intended for gel electrophoresis of DNA fragments or PCR products....
Xanthine Oxidase (Bovine Buttermilk). Monospecific by IEP. Some cross reactivity with Xanthine Oxidase of other species and tissues may occur....
...
Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...
Biology Products: